Isoniazid-resistant tuberculosis in Denmark: Mutations, transmission and treatment outcome

Journal of Infection

Volumn 60, Issue 6, 2010, Pages 452-457

  Bang, Didi ^a   Andersen, Peter Henrik ^a   Andersen, Åse Bengaard ^b   Thomsen, Vibeke Østergaard ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

InhA; KatG; Resistance; Restriction fragment length polymorphism; RpoB; Therapy

Indexed keywords

BACTERIAL PROTEIN; CLARITHROMYCIN; ETHAMBUTOL; INHA PROTEIN; ISONIAZID; KATG PROTEIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM CULTURE; CONTROLLED STUDY; DENMARK; EXTRAPULMONARY TUBERCULOSIS; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MUTATIONAL ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; PREDICTION; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; DENMARK; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; ISONIAZID; MALE; MUTATION; MYCOBACTERIUM TUBERCULOSIS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RETROSPECTIVE STUDIES; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 77953325018     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2010.03.017     Document Type: Article

References (30)

1. Jindani A., Aber V.R., Edwards E.A., Mitchison D.A. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980, 121:939-949.
2. Mitchison D.A. The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med 2005, 171:699-706.
3. World Health Organization Guidelines for the programatic management of drug-resistant tuberculosis. Emergency update 2008, WHO/HTM/TB/2008.402, WHO, Geneva.
4. Thomsen V.O., Bauer J., Lillebaek T., Glismann S. Results from 8 yrs of susceptibility testing of clinical Mycobacterium tuberculosis isolates in Denmark. Eur Respir J 2000, 16:203-208.
5. Fine P.E., Small P.M. Exogenous reinfection in tuberculosis. N Engl J Med 1999, 341:1226-1227.
6. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987, 136:1339-1342. Hong Kong Chest Service/British Medical Research Council.
7. Hillemann D., Weizenegger M., Kubica T., Richter E., Niemann S. Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2005, 43:3699-3703.
8. Musser J.M., Kapur V., Williams D.L., Kreiswirth B.N., van Soolingen D., van Embden J.D. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J Infect Dis 1996, 173:196-202.
9. Mokrousov I., Narvskaya O., Otten T., Limeschenko E., Steklova L., Vyshnevskiy B. High prevalence of katG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001. Antimicrob Agents Chemother 2002, 46:1417-1424.
10. Zhang M., Yue J., Yang Y.P., Zhang H.M., Lei J.Q., Jin R.L., et al. Detection of mutations associated with isoniazid resistance in Mycobacterium tuberculosis isolates from China. J Clin Microbiol 2005, 43:5477-5482.
11. Telenti A., Honoré N., Bernasconi C., March J., Ortega A., Heym B., et al. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J Clin Microbiol 1997, 35:719-723.
12. Vijdea R., Stegger M., Sosnovskaja A., Andersen A.B., Thomsen V.O., Bang D. Multidrug-resistant tuberculosis: rapid detection of resistance to rifampin and high or low levels of isoniazid in clinical specimens and isolates. Eur J Clin Microbiol Infect Dis 2008, 27:1079-1086.
13. van Embden J.D., Cave M.D., Crawford J.T., Dale J.W., Eisenach K.D., Gicquel B., et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993, 31:406-409.
14. Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis 2001, 5:213-215.
15. Crofton J., Chaulet P., Maher D. Guidelines for the management of drug-resistant tuberculosis 1997, WHO/TB/96.210 (Rev 1), WHO, Geneva.
16. World Health Organization Anti-tuberculosis drug resistance in the world 2008, Report No. 4. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. WHO/HTM/TB/2008.394, WHO, Geneva.
17. Clinical and Laboratory Standards Institute Susceptibility testing of Mycobacteria, Nocardiae, and other Aerobic Actinomycetes; approved standard M24-A 2003, CLSI, Wayne, Pennsylvania.
18. Lillebaek T., Poulsen S., Kok-Jensen A. Tuberculosis treatment in Denmark: treatment outcome for all Danish patients in 1992. Int J Tuberc Lung Dis 1999, 3:603-612.
19. Epi-News National surveillance of communicable diseases. Tuberculosis 2000-2005, Department of Epidemiology, Statens Serum Institut, Copenhagen.
20. Espinal M.A., Kim S.J., Suarez P.G., Kam K.M., Khomenko A.G., Migliori G.B., et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000, 283:2537-2545.
21. Farah M.G., Tverdal A., Steen T.W., Heldal E., Brantsaeter A.B., Bjune G. Treatment outcome of new culture positive pulmonary tuberculosis in Norway. BMC Public Health 2005, 5:14.
22. Cattamanchi A., Dantes R.B., Metcalfe J.Z., Jarlsberg L.G., Grinsdale J., Kawamura L.M., et al. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis 2009, 48:179-185.
23. Mitchison D.A., Nunn A.J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986, 133:423-430.
24. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Treatment of tuberculosis. Am J Respir Crit Care Med 2003, 167:603-662.
25. Babu S.O., Aluoch J.A., Githui W.A., Thiong'o R., Edwards E.A., Darbyshire J.H., et al. Controlled clinical trial of a regimen of two durations for the treatment of isoniazid resistant pulmonary tuberculosis. Tubercle 1988, 69:5-14.
26. Dorman S.E., Johnson J.L., Goldberg S., Muzanye G., Padayatchi N., Bozeman L., et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009, 180:273-280.
27. Moadebi S., Harder C.K., Fitzgerald M.J., Elwood K.R., Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007, 67:2077-2099.
28. Moulding T.S. Should isoniazid be used in retreatment of tuberculosis despite acquired isoniazid resistance?. Am Rev Respir Dis 1981, 123:262-264.
29. Katiyar S.K., Bihari S., Prakash S., Mamtani M., Kulkarni H. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008, 12:139-145.
30. Kan B., Berggren I., Ghebremichael S., Bennet R., Bruchfeld J., Chryssanthou E., et al. Extensive transmission of an isoniazid-resistant strain of Mycobacterium tuberculosis in Sweden. Int J Tuberc Lung Dis 2008, 12:199-204.